Posts Tagged ‘weight bias’

Clicks rule the internet and much of social media, so rudeness is rather easy to find, but hard to take. Reporting that brings insight and understanding is more rare and more rewarding. On obesity yesterday, we found a sharp contrast between promoting insight and promoting contempt. From the Shorenstein Center on Media, Politics and Public […]

We are living is a time of concern about mistrust, misinformation, and polarization. Edelman has been warning us for years now about deepening distrust that promotes misinformation because people do not know what to believe. It promotes polarization because they come to trust only people with beliefs similar to their own. As we confront misinformation, healthy […]

Yesterday, we had the opportunity to offer (and gain) perspective on stigma and discrimination related to obesity. It came in the rich context of a three hour discussion on “Ethics, Equity, and Stigma in Obesity Treatment and Policy.” The Division of Medical Ethics  of NYU School of Medicine co-sponsored the discussion with the Comprehensive Program […]

“You’re either invisible, or the answer is to lose weight, even with mental health.” This is the sentiment that surfaced at OW2023 in research of lived experiences from people coping with both obesity and needing treatment for mental health concerns. It becomes acutely important as we learn that drug trials for conditions other than obesity […]

For one of his fat-hating laugh lines, Bill Maher asks, “Have you ever have seen a fat 90-year old?” As a matter of fact, that describes a parent or grandparent for any number of our friends. It’s not really funny. It is merely one more way the empathy-challenged Maher betrays his ignorance about obesity. But […]

Over the last four years, we’ve been through a lot – not all of it especially good. But the view from OW2023 as it starts today in Dallas points to a pivotal year for obesity care. A good year. Dare we say it. The world seems to be pivoting toward a much more helpful approach […]

We have mixed feelings about a new report in JAMA this week about GLP-1 agonists and the associated risk of gastrointestinal adverse events. On one hand, this is helpful data. It is a reminder that despite all of the sensational reporting about “weight loss miracles,” these drugs are serious medicines that require careful prescribing and […]

Two professors yesterday at the EASD meeting engaged in a fierce and collegial debate about the feasibility of lasting remission in type 2 diabetes with very low calorie diets. Professor Kamlesh Khunti brought a polished presentation of objective data. He was unequivocal. Is lasting remission feasible in a real world setting? “It’s a definite no […]

The Wegovy brand of semaglutide has finally come to the UK this week – albeit in limited quantities. So in the Guardian, Zoe Williams wonders if this will mean the end to blathering about obesity: “Despite this being a breakthrough, it is going to pose an immense challenge to those, in medicine and beyond, who […]

In the midst of an argument for lifestyle as the “cornerstone” for dealing with obesity, Frank Hu recently made a point with which we agree. He expressed the importance of GLP-1 agonists for obesity and warned that issues with access could bring wider health disparities. Because pricing of these drugs, health insurance, and weight-related biases […]